Health
The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements
SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held fromMarch 29th toApril 1st, 2024, in Shenzhen, China. The TICSSO was initiated by Prof. Xinghua Pan (Southern Medical University), Prof. Fuchou Tang (Peking Un...
2024-04-09 23:14
1384
BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3
SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (...
2024-04-09 22:10
1080
Datasea Announces Intent of its CEO to Purchase Up $3,000,000 of its Common Stock in Open Market Purchases
BEIJING, April 9, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and Ch...
2024-04-09 22:00
2851
Meeting the Future | TIANMA Makes a Strong Appearance at 2024 Embedded World
NUREMBERG, Germany, April 9, 2024 /PRNewswire/ -- The world's largest embedded exhibition—— Embedded World 2024, is being held grandly at the Exhibition Centre Nuremberg from 9th to 11th April. Numerous leading companies around the world have brought exciting technologies and innovative services....
2024-04-09 22:00
1080
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2024-04-09 20:00
1142
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivat...
2024-04-09 19:59
841
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentatio...
2024-04-09 19:00
990
GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at ...
2024-04-09 19:00
1312
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system
AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center became the first in the nation to use a novel pulsed field ablation (PFA) system to treat patients with paroxysmal and persistent atrial fibrillation, a...
2024-04-09 18:15
1169
Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA
* Sales double in the USA, order intake increases by over 150 percent * More than 50 percent increase in order intake in EMEA * Business Area Technology & Services' sales grow by almost 25 percent * Further improvement in profitability * Exyte CEO Büchele: "Our follow-the-client strategy ...
2024-04-09 17:52
1381
China's Yunhong Group inks cooperation to support overseas expansion
BEIJING, April 9, 2024 /PRNewswire/ -- On April 3, the signing ceremony between
Global Digital Trade Port (Hainan) Enterprise Management Co., Ltd. and Yunhong
Group was held inBeijing, and the two sides will carry out in-depth cooperation
in the field of health food.
2024-04-09 15:50
1093
Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors
News Summary: * New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi. * Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted anal...
2024-04-09 14:00
1289
Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
PRINCETON, N.J. and SUZHOU, China, April 9, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilen...
2024-04-09 09:18
1304
Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib
SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patient...
2024-04-09 08:30
1081
Yunkang Group participated in S&P Global CSA for the first time Ranks above 89% of participating global peers
HONG KONG, April 9, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its score in the "S&P Global Corporate Sustainability Assessment" ("S&P Global CSA"). The Group was invited to partic...
2024-04-09 07:33
3032
Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR
SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced thatthe positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb)combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or ...
2024-04-09 04:53
1360
Nano Labs Files Annual Report on Form 20-F for Fiscal Year 2023
HANGZHOU, China, April 8, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider inChina, announced today that it filed its annual report on Form 20-F for the fiscal year endedDecember...
2024-04-09 04:45
2849
TraceLink Named a Leader in IDC MarketScape: Worldwide Multi-Enterprise Supply Chain Commerce Network Vendor Assessment
BOSTON, April 9, 2024 /PRNewswire/ -- TraceLink Inc. has been named a leader in the IDC MarketScape: Worldwide Multi-Enterprise Supply Chain Commerce Network 2023 Vendor Assessment (doc #US49948423,December 2023). We believe this recognition underscores TraceLink's transformative role in orchestr...
2024-04-09 01:00
1234
The first press conference with cats was held in Colombia
* To present the first Casa de Adopción de Amores Imposibles [House of Adoption of Impossible Loves] inColombia, as part of its Adopt Your Allergies campaign, Sanofi held the country's first press conference with cats, giving journalists and content creators the opportunity to meet with the fel...
2024-04-08 22:27
1306
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the market...
2024-04-08 22:00
990
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 312 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 293 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 284 media titles]
2024-04-12 15:14
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
[Picked up by 272 media titles]
2024-04-11 11:00
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 272 media titles]
2024-04-15 08:00
Most Read
LEGOLAND® School Challenge 2024 Expands Across Asia and Opens for Registration on April 15th
2024-04-11 11:00
5731
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
5023
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
3872
Cognizant Teams with Shopify and Google Cloud To Transform Enterprise Retail
2024-04-09 12:01
3408
PENSKE AUTOMOTIVE GROUP TO EXPAND RETAIL AUTOMOTIVE PRESENCE INTO AUSTRALIA
2024-04-09 04:15
3211